| [1] |
Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline[J]. J Clin Oncol, 2024, 42(28): 3355-3375. DOI: 10.1200/jco.24.01160.
|
| [2] |
Lin ZY, Zhang P, Chi P, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase Ⅲ trial[J]. Ann Oncol, 2024, 35(10): 882-891. DOI: 10.1016/j.annonc.2024.06.015.
pmid: 38964714
|
| [3] |
Conroy T, Castan F, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial[J]. Ann Oncol, 2024, 35(10): 873-881. DOI: 10.1016/j.annonc.2024.06.019.
pmid: 38986769
|
| [4] |
Xia F, Wang Y, Wang H, et al. Randomized phase Ⅱ trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)[J]. J Clin Oncol, 2024, 42(28): 3308-3318. DOI: 10.1200/jco.23.02261.
|
| [5] |
Zhang ZF, Liu X, Chen DW, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment[J]. Sig Transduct Target Ther, 2022, 7(1): 258. DOI: 10.1038/s41392-022-01102-y.
|
| [6] |
Yin LM, Xue JX, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. IJROBP, 2020, 108(1): 212-224. DOI: 10.1016/j.ijrobp.2020.05.002.
|
| [7] |
Tian F, Dai HH, Sha D, et al. Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial[J]. Lancet Oncol, 2025, 26(8): 1043-1054. DOI: 10.1016/s1470-2045(25)00286-4.
pmid: 40645192
|
| [8] |
Amatu A, Patelli G, Zampino MG, et al. Total neoadjuvant therapy followed by non-operative management or surgery in stage Ⅱ-Ⅲ rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2025, 26(12): 1612-1625. DOI: 10.1016/s1470-2045(25)00542-x.
|
| [9] |
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus non-operative treatment for stage 0 distal rectal cancer following chemo-radiation therapy[J]. Ann Surg, 2004, 240(4): 711-718. DOI: 10.1097/01.sla.0000141194.27992.32.
pmid: 15383798
|
| [10] |
Pei JP, Xu HJ, Dong QS, et al. Applicability of cCR assessment criteria in pMMR rectal cancer patients treated with neoadjuvant chemoradiotherapy combined with immunotherapy[J]. Int J Surg, 2025, 111(10): 6604-6613. DOI: 10.1097/js9.0000000000002795.
|
| [11] |
中国直肠癌新辅助治疗后等待观察数据库研究协作组, 中华医学会外科学分会结直肠外科学组, 中国医师协会结直肠肿瘤医师专业委员会, 等. 直肠癌新辅助治疗后等待观察策略中国专家共识(2024版)[J]. 中华胃肠外科杂志, 2024, 27(4): 301-315.DOI: 10.3760/cma.j.cn441530-20240227-00075.
|
| [12] |
Custers PA, Beets GL, Bach SP, et al. An international expert-based consensus on the definition of a clinical near-complete response after neoadjuvant (Chemo)radiotherapy for rectal cancer[J]. Dis Colon Rectum, 2024, 67(6): 782-795. DOI: 10.1097/dcr.0000000000003209.
pmid: 38701503
|
| [13] |
韩加刚, 孙丽婷, 翟志伟, 等. 多点全层穿刺活检对新辅助治疗后直肠癌缓解程度判断指导价值的前瞻性多中心研究[J]. 中华外科杂志, 2023, 61(9): 768-774. DOI: 10.3760/cma.j.cn112139-20230417-00170.
|
| [14] |
Caruso R, Vicente E, Quijano Y, et al. Role of 18F-PET-CT to predict pathological response after neoadjuvant treatment of rectal cancer[J]. Discov Oncol, 2021, 12(1): 16. DOI: 10.1007/s12672-021-00405-w.
|
| [15] |
López-López V, Abrisqueta Carrión J, Luján J, et al. Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series[J]. Rev Esp Enferm Dig, 2020, 113(5):307-312. DOI: 10.17235/reed.2020.6954/2020.
|
| [16] |
Tokmak H, Demir N, Çulpan HC. Total lesion glycolysis (TLG) on 18F-FDG PET/CT as a potential predictor of pathological complete response in locally advanced rectal cancer after total neoadjuvant therapy: a retrospective study[J]. Diagnostics (Basel), 2025, 15(14): 1800. DOI: 10.3390/diagnostics15141800.
|
| [17] |
Wu FP, Zhang XX, Yang CR, et al. The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression[J]. Front Oncol, 2022, 12: 1037783. DOI: 10.3389/fonc.2022.1037783.
|
| [18] |
Lambregts DMJ, Maas M, Boellaard TN, et al. Long-term imaging characteristics of clinical complete responders during watch-and-wait for rectal cancer—an evaluation of over 1500 MRIs[J]. Eur Radiol, 2020, 30(1): 272-280. DOI: 10.1007/s00330-019-06396-1.
pmid: 31428827
|
